“We’re open for business,” said Taiho Oncology, Inc. CEO, Timothy Whitten. Alongside its growing pipeline of orally administered oncology drugs, the US subsidiary of Japan’s Taiho ...

The Series A was led by founding investor Versant Ventures with participation from Mubadala Capital, Bristol Myers Squibb, ...

Taiho Oncology, Inc. announced today presentations at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

TAS-0728 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Endometrial Cancer.

Studies highlight the company's ongoing commitment to advancing care for patients with myeloid malignancies Findings from a Phase 1 dose escalation trial of ASTX030, an investigational combination ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Taiho Oncology has a robust pipeline of small molecule clinical candidates targeting solid tumor and hematological malignancies, with additional candidates in pre-clinical development.

PRINCETON, N.J., Dec. 9, 2024 /PRNewswire/ -- Taiho Oncology, Inc., presented results of two studies focused on oral therapies for patients with myelodysplastic syndromes (MDS) and MDS ...